SCHEMBL4294981

SCHEMBL4294981

O=C(O)N1C=COC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3356550 0.74
SCHEMBL5798660 0.71
Bicarbonate SCHEMBL31738461 0.69
SCHEMBL4073685 0.69
Water SCHEMBL8221741 0.67
SCHEMBL31481251 0.65 MEN1 (0.36)
SCHEMBL3262997 0.65
Oxalic Acid SCHEMBL11567656 0.56
Benzene SCHEMBL88325 0.55
SCHEMBL56545 0.54

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7332354-B2 Compounds for chemiluminescense procedures ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2008-02-19 US claimed
US-20260015321-A1 CHEMICAL COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) 2026-01-15 US disclosed
US-12466842-B2 Substituted pyrido [4,3-d]pyrimidines as KRAS modulators ALTEROME THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
WO-2025149628-A1 PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE ASTRAZENECA AB (SE) 2025-07-17 WO disclosed
EP-4583977-A1 HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-07-16 EP disclosed
WO-2024175081-A1 SHP2 INHIBITOR COMPOUND AND USE THEREOF 深圳真实生物医药科技有限公司 2024-08-29 WO disclosed
WO-2024125464-A1 TETRAHYDROISOQUINOLIN-ONE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-06-20 WO disclosed
CN-116283916-B Compound with Axl and c-Met kinase inhibition activity and preparation and application thereof 中国科学院上海药物研究所 2024-06-11 CN disclosed
CN-118103369-A Pyridolactam derivatives, preparation method and application thereof 浙江海正药业股份有限公司 2024-05-28 CN disclosed
WO-2024088351-A1 COMPOUNDS AND USES THEREOF SUZHOU ZANRONG PHARMA LIMITED (CN) 2024-05-02 WO disclosed
CN-1933853-A Drug conjugates UNIV NEW YORK (US) 2007-03-21 CN disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 EP disclosed
CN-1653054-A Benzoxazine derivatives as 5-HT 6 modulators and uses thereof HOFFMANN LA ROCHE (CH) 2005-08-10 CN disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 WO disclosed
US-20040214999-A1 Novel compounds for chemiluminescense procedures ROCHE DIAGNOSTICS OPERATIONS, INC. 2004-10-28 US disclosed
WO-2004037829-A1 NOVEL BENZOXAZOLE OR OXAZOLOPYRIDINE COMPOUNDS, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2004-05-06 WO disclosed
EP-1397678-A1 LUCIFERIN HYDRAZIDES Roche Diagnostics GmbH (DE) 2004-03-17 EP disclosed
EP-1397488-A1 NOVEL COMPOUNDS FOR CHEMILUMINESCENSE PROCEDURES Roche Diagnostics GmbH (DE) 2004-03-17 EP disclosed
WO-2002099428-A1 LUCIFERIN HYDRAZIDES ROCHE DIAGNOSTICS GMBH (DE) 2002-12-12 WO disclosed
WO-2002099097-A1 NOVEL COMPOUNDS FOR CHEMILUMINESCENSE PROCEDURES ROCHE DIAGNOSTICS GMBH (DE) 2002-12-12 WO disclosed